Applus+ Appoints Richard Bartlett as Chief Executive Officer
Joan Amigó I Casas to become Senior Advisor to the Board
Applus+, a global leader in testing, inspection and certification services with headquarters in Barcelona, is pleased to announce a new chapter in its leadership.
Effective 7 April 2025, Joan Amigó I Casas, who has served as Chief Executive Officer of Applus+ since 2022, has elected to step down from his current position and take on a newly created role as Senior Advisor to the Board. In this capacity, Joan will report to Mike Smith, the recently appointed Chairman of Applus+, and focus on strengthening Government and State relations and leading strategic projects of national significance. He will also continue to serve on the Boards of IDIADA and LGAI.
Mike Smith, Chairman of Applus+, said: “Joan has overseen significant growth in Applus+ during his time as CEO and has guided the business through the transition from public to private ownership. We are very grateful for his contribution and delighted that he has agreed to be a Senior Advisor to the Board.”
Applus+ is also pleased to announce that Richard Bartlett has been appointed as the new Chief Executive Officer and will assume the role in June 2025. Richard joins from BP, where he most recently served as CEO of BP Pulse, the company’s global electric vehicle charging business and as head of BP’s European Fuel and Convenience retail business.During his career at BP, he also held senior leadership roles including CFO of air bp and BP Asia Pacific.
Commenting on the appointment of Richard Bartlett, Mike Smith, Chairman of Applus+, said: “We are delighted to welcome Richard to Applus. He brings a strong track record of leadership in complex, global businesses. His international experience, commercial acumen, and people-focused leadership style make him ideally suited to lead Applus through its next phase of development.”
A fluent Spanish speaker, Richard and his family will be relocating to Spain.
In the interim period between Joan’s transition on 7 April and Richard’s arrival in June, the Applus+ Executive Team will report directly to Chairman Mike Smith.
This announcement marks a significant milestone in the evolution of Applus+ under its new ownership, with a strengthened leadership team and renewed strategic focus for continued global growth.
Notes to Editors
About Applus+
Applus+ is one of the world's leading testing, inspection and certification (TIC) companies. Applus+ reported revenue of €2,058 million in 2023 and employs over 26,000 people in more than 70 countries. With headquarters in Barcelona, revenue generated from the home country of Spain accounted for 23% of the total. Applus+ addresses three deep and broad markets: automotive, energy and industry and laboratories.
About I Squared Capital
I Squared is a leading independent global infrastructure investor managing over $40 billion in assets. We build investment platforms from the ground up—starting small and scaling big. Combining global insight with local expertise, we tackle complex challenges, back smarter businesses, and invest in sustainable infrastructure that delivers essential services to millions worldwide. Our team of 280+ is headquartered in Miami with offices in Abu Dhabi, London, Munich, New Delhi, São Paulo, Singapore, Sydney, and Taipei. We manage a diverse portfolio of 89 companies across 70+ countries, employing over 66,000 people in sectors including utilities, energy, digital infrastructure, transport, environmental, and social infrastructure. Learn more at www.isquaredcapital.com.
About TDR Capital
TDR Capital LLP is a leading European private equity firm with over €15 billion of assets under management. Founded in 2002, TDR typically acquires majority stakes in strong, market-leading European companies with the potential for robust growth and resilience throughout economic cycles. The firm has managed five European mid-market buyout funds. The team of 61 professionals currently manages assets across four European mid-market buyout funds from its headquarters in London. To date, the firm has made 27 platform investments, and its portfolio companies employ over 270,000 people around the world. TDR takes a long-term approach to investment and, in addition to capital invested, also provides expert resource to help drive sustainable value creation and positive, transformational change within the businesses it owns. For more information, visit tdrcapital.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250402671715/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom